Formula Growth’s Avanos Medical AVNS Stock Holding History

Formula Growth’s Portfolio AVNS Stock Details AVNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-73,457	Closed	-$3.2M	–	150
2019 Q2	$3.2M	Buy	+73,457	New	+$3.14M	0.46%	58

Other funds holding AVNS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PIM

Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Formula Growth's AVNS Position: Q3 2019 in Review

Formula Growth sold out of Avanos Medical (AVNS) in Q3 2019, closing a stake of 73,457 shares — an estimated $3.2M sold.

Formula Growth first reported a position in AVNS in Q2 2019 and held it in 1 quarter. The position peaked at $3.2M in Q2 2019. 290 funds tracked by Wall St. Rank hold AVNS as of Q3 2019.

Formula Growth reported no remaining Avanos Medical position as of Q3 2019 after selling out during the quarter.
Formula Growth sold 73,457 Avanos Medical shares in Q3 2019, an estimated $3.2M.
Formula Growth first reported a position in Avanos Medical in Q2 2019 and held it in 1 quarter.
Formula Growth's Avanos Medical position peaked at $3.2M in Q2 2019.
290 funds tracked by Wall St. Rank held Avanos Medical as of Q3 2019.

Based on Formula Growth's 13F filing for Q3 2019, filed 14 Nov 2019.